Mraz Amerine & Associates’s Amgen AMGN Stock Holding History

Mraz Amerine & Associates’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Sell	7,668 -44	-0.6%	-$15.1K	0.4%	44
2026 Q1	$2.71M	Sell	7,712 -1,083	-12%	-$386K	0.4%	46
2025 Q4	$2.88M	Sell	8,795 -120	-1%	-$38.1K	0.43%	36
2025 Q3	$2.52M	Sell	8,915 -133	-1%	-$38.6K	0.39%	38
2025 Q2	$2.53M	Buy	9,048 +249	+3%	+$70.5K	0.41%	37
2025 Q1	$2.7M	Buy	8,799 +57	+0.7%	+$16.8K	0.46%	33
2024 Q4	$2.28M	Buy	8,742 +1,718	+24%	+$510K	0.41%	38
2024 Q3	$2.26M	Hold	7,024	–	–	0.41%	37
2024 Q2	$2.19M	Buy	7,024 +577	+9%	+$170K	0.45%	37
2024 Q1	$1.83M	Buy	6,447 +376	+6%	+$110K	0.35%	50
2023 Q4	$1.75M	Buy	6,071 +1	+0%	+$272	0.37%	49
2023 Q3	$1.63M	Buy	6,070 +478	+9%	+$119K	0.37%	51
2023 Q2	$1.24M	Sell	5,592 -115	-2%	-$26.7K	0.29%	66
2023 Q1	$1.38M	Buy	5,707 +515	+10%	+$126K	0.34%	55
2022 Q4	$1.36M	Hold	5,192	–	–	0.32%	54
2022 Q3	$1.17M	Hold	5,192	–	–	0.31%	57
2022 Q2	$1.26M	Sell	5,192 -50	-1%	-$12.3K	0.32%	56
2022 Q1	$1.27M	Buy	5,242 +1	+0%	+$230	0.3%	62
2021 Q4	$1.18M	Hold	5,241	–	–	0.3%	60
2021 Q3	$1.11M	Hold	5,241	–	–	0.3%	63
2021 Q2	$1.28M	Hold	5,241	–	–	0.35%	48
2021 Q1	$1.3M	Hold	5,241	–	–	0.38%	44
2020 Q4	$1.21M	Sell	5,241 -100	-2%	-$23.1K	0.4%	35
2020 Q3	$1.36M	Buy	5,341 +1	+0%	+$248	0.5%	27
2020 Q2	$1.26M	Sell	5,340 -540	-9%	-$123K	0.47%	31
2020 Q1	$1.19M	Buy	5,880 +430	+8%	+$93.9K	0.47%	24
2019 Q4	$1.31M	Sell	5,450 -50	-0.9%	-$11K	0.38%	42
2019 Q3	$1.06M	Buy	5,500 +12	+0.2%	+$2.3K	0.32%	45
2019 Q2	$1.01M	Hold	5,488	–	–	0.3%	47
2019 Q1	$1.04M	Sell	5,488 -458	-8%	-$87.5K	0.32%	46
2018 Q4	$1.16M	Sell	5,946 -50	-0.8%	-$9.76K	0.38%	44
2018 Q3	$1.24M	Buy	5,996 +1	+0%	+$197	0.37%	48
2018 Q2	$1.11M	Buy	5,995 +300	+5%	+$53.1K	0.34%	51
2018 Q1	$971K	Sell	5,695 -680	-11%	-$125K	0.31%	51
2017 Q4	$1.11M	Sell	6,375 -148	-2%	-$26.2K	0.34%	51
2017 Q3	$1.22M	Sell	6,523 -471	-7%	-$83.5K	0.38%	45
2017 Q2	$1.2M	Buy	6,994 +2	+0%	+$325	0.37%	48
2017 Q1	$1.14M	Buy	6,992 +2	+0%	+$332	0.36%	47
2016 Q4	$1.02M	Buy	6,990 +1,281	+22%	+$193K	0.32%	51
2016 Q3	$952K	Buy	5,709 +2	+0%	+$338	0.33%	47
2016 Q2	$868K	Buy	5,707 +1	+0%	+$155	0.3%	51
2016 Q1	$855K	Buy	5,706 +2	+0%	+$297	0.31%	48
2015 Q4	$926K	Buy	5,704 +1	+0%	+$157	0.35%	44
2015 Q3	$789K	Buy	5,703 +17	+0.3%	+$2.68K	0.31%	51
2015 Q2	$873K	Sell	5,686 -98	-2%	-$15.7K	0.33%	52
2015 Q1	$925K	Buy	5,784 +1	+0%	+$157	0.35%	51
2014 Q4	$921K	Sell	5,783 -200	-3%	-$31.2K	0.35%	48
2014 Q3	$840K	Buy	5,983 +1	+0%	+$131	0.32%	56
2014 Q2	$708K	Buy	5,982 +1	+0%	+$116	0.27%	63
2014 Q1	$738K	Buy	5,981 +1	+0%	+$121	0.31%	52
2013 Q4	$682K	Buy	5,980 +1	+0%	+$114	0.3%	55
2013 Q3	$669K	Buy	5,979 +1	+0%	+$108	0.32%	50
2013 Q2	$590K	Buy	+5,978	New	+$620K	0.3%	56

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Mraz Amerine & Associates's AMGN Position: Q2 2026 in Review

Mraz Amerine & Associates reduced its Amgen (AMGN) stake by 0.57% in Q2 2026, selling an estimated $15.1K and leaving 7,668 shares worth $2.78M. The position accounts for 0.4% of the portfolio, ranked #44.

Mraz Amerine & Associates first reported a position in AMGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.88M in Q4 2025. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

Mraz Amerine & Associates held 7,668 shares of Amgen worth $2.78M as of Q2 2026.
Mraz Amerine & Associates sold 44 Amgen shares in Q2 2026, an estimated $15.1K.
Amgen made up 0.4% of Mraz Amerine & Associates's portfolio in Q2 2026, its #44 holding.
Mraz Amerine & Associates first reported a position in Amgen in Q2 2013 and has held it in 53 quarters since.
Mraz Amerine & Associates's Amgen position peaked at $2.88M in Q4 2025.
3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Mraz Amerine & Associates's 13F filing for Q2 2026, filed 16 Jul 2026.